Session 112 - 12th CROI

Home

Session 112 Poster Abstracts
Pharmacology of NNRTIs
Wednesday, 1:30 - 3:30 pm
Hall A

650	Relevance of Drug Transporters and Drug Metabolism Enzymes to Nevirapine: Superimposition of Host Genotype Andrew Owen*¹, L Almond¹, R Hartkoorn¹, T Walsh¹, M Youle², A Bonington³, F Turner², C Smith², A M Garretti², A Phillips², O Janneh¹, D Back¹, and S Khoo¹ ¹Liverpool Univ, UK; ²Royal Free Hosp, London, UK; and ³North Manchester Gen Hosp, UK
651	Pharmacogenetics of Efavirenz and Selective Pressure for Drug Resistance after Treatment Discontinuation: NWCS214, an Analysis of ACTG Studies A5095/A5097S David W Haas*¹, H Ribaudo², R Kim¹, C Tierney², G Wilkinson¹, R Gulick³, D Clifford⁴, C Marzolini¹, and E Acosta⁵ ¹Vanderbilt Univ, Nashville, TN, USA; ²Harvard Sch of Publ Hlth, Boston, MA, USA; ³Weill Med Coll, Cornell Univ, New York, NY, USA; ⁴Washington Univ Sch of Med, St Louis, MO, USA; and ⁵Univ of Alabama at Birmingham, USA
652	G516T Polymorphism at the CYP2B6 Isoenzyme Significantly Influences Efavirenz Plasma Levels and the Risk of Neurological Symptoms Sonia R-Novoa*, P Barreiro, A Rendon, J Gonzalez-Lahoz, and V Soriano Hosp Carlos III, Madrid, Spain
653	Efavirenz Decreases Buprenorphine Exposure, but Is Not Associated with Opiate Withdrawal in Opioid Dependent Individuals EF McCance-Katz*¹, P Pade¹, G Friedland², G Morse³, D Moody⁴, and P Rainey⁵ ¹Richmond, Virginia; ²New Haven, CT, USA; ³Buffalo, NY, USA; ⁴Salt Lake City, Utah; and ⁵Seattle, Washington